Resuming the use of Johnson & Johnson's (JNJ.N) COVID-19 vaccine in the United States will require clear guidelines for the medical community on how to best treat patients that develop a rare type of blood clot, as well as alerting vaccine recipients to be aware of the telltale symptoms, according to heart doctors and other medical experts.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.